Aussie pharma development company Algorae Pharmaceuticals (ASX: 1AI) has partnered with HL Pharma, an Australian company registered with the Victorian Department of Health, for the sourcing, supply, and distribution of various cannabinoid compounds for research purposes. The collaboration is governed by a comprehensive three-year agreement, adhering to Good Distribution Practice (GDP). Under the terms, HL
Read More
Autism Spectrum Disorder (ASD) affects 1 in 150 Australians. Boys are 4 times more likely to have it than girls, and symptoms are noticeable at around 2-3 years of age. According to the Australian Institute of Health and Welfare, the number of people with ASD in Australia is increasing, providing an impetus for biopharmaceutical company
Read More
There is an increasingly growing body of research globally into the use of psychedelic medicines to treat various health conditions. To date, this research has produced highly encouraging results and has promoted the development of an extensive psychedelic industry, which has kicked off in North America and the United Kingdom. The industry has now made
Read More
It wasn’t too long ago that I was in the shower, holding my squirming dog’s paws in a washing basket filled with an oatmeal concoction, whilst smearing peanut butter on the shower wall for her to lick. Why, you ask? Because my baby gets itchy paws (and I’m a great dog mom). Itchy paws and
Read More
Unsurprisingly, four out of ten adults experience regular poor sleep. We all know the consequences of a bad night’s rest on our health, performance and mood, as well as the crippling caffeine addiction that develops. *Sips double shot oat milk latte* People with Obstructive Sleep Apnoea (OSA) have it worse. OSA is characterised by partial
Read More
Pharmaceuticals company Emyria (ASX: EMD) is set to commence the regulatory process of registering their cannabinoid-based medicine EMD-003 as a treatment to reduce symptoms of mental health disorders, leveraging extensive data gathered from their network of clinics. Initial evidence collected by Emyria’s subsidiary Emerald Clinics has identified an unmet need by targeting the treatment of
Read More